×
News Home

Is ImmunoGen, Inc. (IMGN) a Stock to Watch After Losing -4.99% This Week?

Friday, January 07, 2022 12:14 PM | InvestorsObserver Analysts
Is ImmunoGen, Inc. (IMGN) a Stock to Watch After Losing -4.99% This Week?

Overall market sentiment has been high on ImmunoGen, Inc. (IMGN) stock lately. IMGN receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bullish
ImmunoGen, Inc. has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on IMGN!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With IMGN Stock Today?

ImmunoGen, Inc. (IMGN) stock is trading at $7.05 as of 12:13 PM on Friday, Jan 7, a loss of -$0.18, or -2.56% from the previous closing price of $7.23. The stock has traded between $6.94 and $7.21 so far today. Volume today is below average. So far 526,617 shares have traded compared to average volume of 6,464,551 shares. To see InvestorsObserver's Sentiment Score for ImmunoGen, Inc. click here.

More About ImmunoGen, Inc.

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have licensed limited rights to use the ADC technology in their therapies. Click Here to get the full Stock Report for ImmunoGen, Inc. stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App